Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain
- 30 January 2004
- journal article
- research article
- Published by Wiley in European Journal of Neuroscience
- Vol. 19 (3) , 678-686
- https://doi.org/10.1111/j.0953-816x.2004.03177.x
Abstract
The antinociceptive effects of Δ9‐tetrahydrocannabinol (Δ9‐THC) have been widely described; however, its therapeutic potential may be limited by secondary effects. We investigated whether coadministration of low doses of cannabinoids or cannabinoids and morphine produced antinociception in the absence of side‐effects. Effects of preadministration (i.p.) of Δ9‐THC (1 or 2.5 mg/kg), cannabidiol (5 mg/kg), morphine (2 mg/kg), Δ9‐THC + morphine, Δ9‐THC + cannabidiol or vehicle on formalin‐evoked nociceptive behaviour were studied over 60 min. Trunk blood and brains were collected 60 min after formalin injection and assayed for corticosterone and tissue levels of monoamines and metabolites, respectively. Drug effects on locomotor activity, core body temperature and grooming were assessed. Δ9‐THC reduced both phases of formalin‐evoked nociceptive behaviour, enhanced the formalin‐evoked corticosterone response and increased the 4‐hydroxy‐3‐methoxyphenylglycol : noradrenaline ratio in the hypothalamus. Cannabidiol alone had no effect on these indices and did not modulate the effects of Δ9‐THC. Morphine reduced both phases of formalin‐evoked nociceptive behaviour. Coadministration of Δ9‐THC and morphine reduced the second phase of formalin‐evoked nociceptive behaviour to a greater extent than either drug alone, and increased levels of thalamic 5‐hydroxytryptamine. While the antinociceptive effects of Δ9‐THC and morphine alone occurred at doses devoid of effects on locomotor activity, coadministration of Δ9‐THC and morphine inhibited locomotor activity. In conclusion, coadministration of a low dose of morphine, but not cannabidiol, with Δ9‐THC, increased antinociception and 5‐hydroxytryptamine levels in the thalamus in a model of persistent nociception. Nevertheless, these enhanced antinociceptive effects were associated with increased secondary effects on locomotor activity.Keywords
This publication has 58 references indexed in Scilit:
- Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in ratsNeuropharmacology, 2003
- The role of the central nucleus of the amygdala in nociception and aversionNeuroReport, 2003
- Pituitary-Adrenocortical Responses to Persistent Noxious Stimuli in the Awake Rat: Endogenous Corticosterone Does Not Reduce Nociception in the Formalin TestEndocrinology, 1998
- Differential Effects of Chronic Treatment with Either Dopamine D1 or D2 Receptor Agonists on the Acute Neuroendocrine Actions of the Highly Potent Synthetic Cannabinoid HU-210 in Male RatsNeuroendocrinology, 1995
- Effect of morphine on hypothalamic catecholamine and serotonin level in relation to the stress-induced pituitary-adrenocortical activation in the ratExperimental and Clinical Endocrinology & Diabetes, 1994
- Opioid-Receptor-Mediated Inhibition of [3H]Dopamine but Not [3H]Noradrenaline Release from Rat Mediobasal Hypothalamus SlicesNeuroendocrinology, 1991
- Effect of 6-hydroxydopamine-induced lesions to ascending and descending noradrenergic pathways on morphine analgesiaBrain Research, 1987
- Differences in Hypothalamo-Pituitary-Adrenocortical Activity in the Rat after Acute and Prolonged Treatment with MorphineNeuroendocrinology, 1984
- ACTH and corticosterone response to naloxone and morphine in normal, hypophysectomized and dexamethasone-treated ratsLife Sciences, 1982
- The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and catsPain, 1977